Skip to main content

Advanced Systemic Mastocytosis

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Blueprint Medicines
Blueprint MedicinesMA - Cambridge
2 programs
BLU-263PHASE_11 trial
AvapritinibPHASE_2Small Molecule1 trial
Active Trials
NCT05609942Terminated9Est. Mar 2025
NCT03580655Completed107Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Blueprint MedicinesAvapritinib
Blueprint MedicinesBLU-263

Clinical Trials (2)

Total enrollment: 116 patients across 2 trials

NCT03580655Blueprint MedicinesAvapritinib

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Start: Nov 2018Est. completion: Dec 2024107 patients
Phase 2Completed
NCT05609942Blueprint MedicinesBLU-263

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Start: Sep 2023Est. completion: Mar 20259 patients
Phase 1Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.